Overview

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Status:
Not yet recruiting

Trial end date:
2028-09-15

Target enrollment:

Participant gender:

Summary

This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborators:

EADO - European Association of Dermato Oncology
European Association of Dermato Oncology
Merck Sharp & Dohme Corp.
Pierre Fabre Medicament

Treatments:

Pembrolizumab